These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31251112)

  • 1. Rapid enrollment design for finding the optimal dose in immunotherapy trials with ordered groups.
    Xue X; Foster MC; Ivanova A
    J Biopharm Stat; 2019; 29(4):625-634. PubMed ID: 31251112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials.
    Zhang Y; Guo B; Cao S; Zhang C; Zang Y
    Pharm Stat; 2022 Sep; 21(5):960-973. PubMed ID: 35332674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A generalized Bayesian optimal interval design for dose optimization in immunotherapy.
    Xia Q; Takeda K; Yamaguchi Y; Zhang J
    Pharm Stat; 2024; 23(4):480-494. PubMed ID: 38295856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials.
    Guo B; Li D; Yuan Y
    Pharm Stat; 2018 Sep; 17(5):527-540. PubMed ID: 29882388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian dose-finding designs for combination of molecularly targeted agents assuming partial stochastic ordering.
    Guo B; Li Y
    Stat Med; 2015 Feb; 34(5):859-75. PubMed ID: 25413162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes.
    Takeda K; Taguri M; Morita S
    Pharm Stat; 2018 Jul; 17(4):383-395. PubMed ID: 29700965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy.
    Zhou Y; Lin R; Lee JJ; Li D; Wang L; Li R; Yuan Y
    Stat Med; 2022 May; 41(11):1918-1931. PubMed ID: 35098585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian design for finding optimal biological dose with mixed types of responses of toxicity and efficacy.
    Zhang D; Xu J
    Contemp Clin Trials; 2023 Apr; 127():107113. PubMed ID: 36758934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy.
    Guo B; Zang Y
    Stat Methods Med Res; 2022 Jun; 31(6):1104-1119. PubMed ID: 35191780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian adaptive model selection design for optimal biological dose finding in phase I/II clinical trials.
    Lin R; Yin G; Shi H
    Biostatistics; 2023 Apr; 24(2):277-294. PubMed ID: 34296266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
    Zang Y; Lee JJ
    Stat Med; 2017 Jan; 36(1):27-42. PubMed ID: 27538818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TITE-gBOIN: Time-to-event Bayesian optimal interval design to accelerate dose-finding accounting for toxicity grades.
    Takeda K; Xia Q; Liu S; Rong A
    Pharm Stat; 2022 Mar; 21(2):496-506. PubMed ID: 34862715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison Between Simultaneous and Sequential Utilization of Safety and Efficacy for Optimal Dose Determination in Bayesian Model-Assisted Designs.
    Li R; Takeda K; Rong A
    Ther Innov Regul Sci; 2023 Jul; 57(4):728-736. PubMed ID: 37087525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rapid enrollment design for Phase I clinical trials.
    Ivanova A; Wang Y; Foster MC
    Stat Med; 2016 Jul; 35(15):2516-24. PubMed ID: 26833922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint.
    Guo B; Zang Y
    Stat Med; 2022 Mar; 41(7):1205-1224. PubMed ID: 34821409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSNP: A two-stage nonparametric phase I/II clinical trial design for immunotherapy.
    Han Y; Liu H; Cao S; Zhang C; Zang Y
    Pharm Stat; 2021 Mar; 20(2):282-296. PubMed ID: 33025762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.